Approval · Notice of Compliance 18907 · 2017
VIBERZI: Notice of Compliance 18907
Issued January 26, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18907
- Date
- January 26, 2017
- Company
- Allergan Pharma Co.Markham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- ELUXADOLINE 75 MG per TAB
- ELUXADOLINE 100 MG per TAB